WO2008093838A1 - スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用 - Google Patents

スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用 Download PDF

Info

Publication number
WO2008093838A1
WO2008093838A1 PCT/JP2008/051655 JP2008051655W WO2008093838A1 WO 2008093838 A1 WO2008093838 A1 WO 2008093838A1 JP 2008051655 W JP2008051655 W JP 2008051655W WO 2008093838 A1 WO2008093838 A1 WO 2008093838A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridyl
sulfamoyl group
pharmaceutical use
imidazolidine derivative
imidazolidine
Prior art date
Application number
PCT/JP2008/051655
Other languages
English (en)
French (fr)
Inventor
Haruhiko Sato
Masateru Ohta
Takashi Emura
Takuya Shiraishi
Kazutaka Tachibana
Akie Honma
Shinichi Arai
Hiromitsu Kawata
Nobuyuki Ishikura
Tadakatsu Takahashi
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of WO2008093838A1 publication Critical patent/WO2008093838A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本発明により、式（Ｉ）： で表される化合物、または医薬として許容されるその塩、および当該化合物を含む医薬組成物が提供される。                                                                               
PCT/JP2008/051655 2007-02-01 2008-02-01 スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用 WO2008093838A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-022799 2007-02-01
JP2007022799 2007-02-01

Publications (1)

Publication Number Publication Date
WO2008093838A1 true WO2008093838A1 (ja) 2008-08-07

Family

ID=39674141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051655 WO2008093838A1 (ja) 2007-02-01 2008-02-01 スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用

Country Status (2)

Country Link
TW (1) TW200846338A (ja)
WO (1) WO2008093838A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029392A1 (en) * 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
EP2538785A1 (en) 2010-02-24 2013-01-02 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
CN112645880A (zh) * 2020-12-29 2021-04-13 山东铂源药业有限公司 一种恩杂鲁胺的合成方法
CN113717166A (zh) * 2021-03-12 2021-11-30 杭州科巢生物科技有限公司 一种普克鲁胺的合成方法
CN113999200A (zh) * 2020-07-28 2022-02-01 苏州科伦药物研究有限公司 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法
CN116199633A (zh) * 2022-12-27 2023-06-02 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04308579A (ja) * 1991-01-09 1992-10-30 Roussel Uclaf 新規なフェニルイミダゾリジン類、それらの製造法、薬剤としての使用及びそれらを含有する製薬組成物
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006028226A1 (ja) * 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha 新規イミダゾリジン誘導体およびその用途
WO2006124118A1 (en) * 2005-05-13 2006-11-23 The Regents Of The University Of California Diarylhydantoin compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04308579A (ja) * 1991-01-09 1992-10-30 Roussel Uclaf 新規なフェニルイミダゾリジン類、それらの製造法、薬剤としての使用及びそれらを含有する製薬組成物
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006028226A1 (ja) * 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha 新規イミダゾリジン誘導体およびその用途
WO2006124118A1 (en) * 2005-05-13 2006-11-23 The Regents Of The University Of California Diarylhydantoin compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOULAOUIC-DUBOIS C. ET AL.: "Efficient reduction of azides with samarium diiodide", TETRAHEDRON LETTERS, vol. 36, no. 41, 1995, pages 7427 - 7430, XP004295887, DOI: doi:10.1016/0040-4039(95)80003-4 *
GOULAOUIC-DUBOIS C. ET AL.: "Protection of Amines by the Pyridine-2-sulfonyl Group and Its Cleavage under Mild Conditions (SmI2 or Electrolysis)", JOURNAL OF ORGANIC CHEMISTRY, vol. 60, no. 18, 1995, pages 5969 - 5972, XP002364116, DOI: doi:10.1021/jo00123a041 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029392A1 (en) * 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
US8809550B2 (en) 2009-09-10 2014-08-19 Youzhi Tong Androgen receptor antagonists and uses thereof
US9174943B2 (en) 2010-02-24 2015-11-03 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
EP3329775A1 (en) * 2010-02-24 2018-06-06 Medivation Prostate Therapeutics LLC Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
EP2538785A1 (en) 2010-02-24 2013-01-02 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
EP2538785B1 (en) * 2010-02-24 2018-03-21 Medivation Prostate Therapeutics LLC Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
CN103608333B (zh) * 2011-03-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
US9216957B2 (en) 2011-03-10 2015-12-22 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
JP2014510074A (ja) * 2011-03-10 2014-04-24 スジョウ キンター ファーマシューティカルズ インコーポレイテッド アンドロゲン受容体アンタゴニストおよびその使用
CN103608333A (zh) * 2011-03-10 2014-02-26 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN113999200A (zh) * 2020-07-28 2022-02-01 苏州科伦药物研究有限公司 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法
CN112645880A (zh) * 2020-12-29 2021-04-13 山东铂源药业有限公司 一种恩杂鲁胺的合成方法
CN113717166A (zh) * 2021-03-12 2021-11-30 杭州科巢生物科技有限公司 一种普克鲁胺的合成方法
CN113717166B (zh) * 2021-03-12 2024-04-05 杭州科巢生物科技有限公司 一种普克鲁胺的合成方法
CN116199633A (zh) * 2022-12-27 2023-06-02 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法

Also Published As

Publication number Publication date
TW200846338A (en) 2008-12-01

Similar Documents

Publication Publication Date Title
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
TW200744588A (en) Pharmaceutical composition for external use
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2007135527A3 (en) Benzimidazolyl compounds
ZA200803414B (en) Novel dihydropseudoerythromycin derivatives
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
WO2009057079A3 (en) Novel pyrimidine derivatives
WO2008123469A1 (ja) ６員環アミド化合物およびその用途
WO2007092642A3 (en) Polymer formulations of cetp inhibitors
WO2009060835A1 (ja) 新規ユビキリン結合性小分子
WO2008153159A1 (ja) アミン化合物及びその医薬用途
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2007099548A3 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
WO2009055289A3 (en) Therapeutic substituted lactams
WO2009038412A3 (en) Beta-secretase inhibiting compounds
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
WO2007018941A3 (en) Pyrimidyl-thiophene derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710699

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08710699

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP